Cardiac Pacing And Electrophysiology — Cost, Top Hospitals & Success Rates | MyMedicPlus

Cardiac pacing and electrophysiology is the subspecialty of cardiology concerned with the diagnosis, investigation, and treatment of disorders of the heart's electrical conduction system — the specialised tissues that generate and conduct the electrical impulses responsible for coordinated heart contraction. These disorders manifest as bradyarrhythmias (abnormally slow heart rates) or tachyarrhythmias (abnormally fast or irregular heart rhythms), either of which can cause symptoms ranging from palpitations and dizziness to syncope, heart failure, and sudden cardiac death.

The two principal treatment pillars are device therapy and catheter ablation. Device therapy — including permanent pacemakers, implantable cardioverter-defibrillators (ICDs), and cardiac resynchronisation therapy (CRT) devices — involves implanting small electronic generators in the chest wall connected via leads (wires) to the heart, providing pacing support, shock therapy, or resynchronised biventricular pacing as appropriate. Catheter ablation uses radiofrequency energy or cryothermy delivered through thin catheters positioned within the heart to destroy small areas of tissue responsible for initiating or sustaining arrhythmias, offering the potential for long-term cure.

Electrophysiology (EP) study is the invasive diagnostic procedure that precedes ablation — recording intracardiac electrograms from multiple sites simultaneously to characterise the mechanism and anatomy of arrhythmias, assess sinus node and AV node function, and induce arrhythmias in a controlled environment to guide treatment decisions. EP study and ablation are increasingly combined in a single sitting, with advanced three-dimensional electroanatomical mapping systems (CARTO, EnSite) providing real-time anatomical-electrical co-registration.

Pacemakers are indicated for symptomatic bradyarrhythmias including sick sinus syndrome (episodes of inappropriate sinus bradycardia, sinus pauses, or alternating bradycardia and tachycardia), complete heart block (failure of conduction between atria and ventricles), second-degree AV block (Mobitz type 2 or high-degree), and chronic bifascicular or trifascicular block with syncope. ICDs are implanted in patients at high risk of sudden cardiac death from ventricular tachyarrhythmias — primarily those with reduced left ventricular ejection fraction (below 35%) due to ischaemic or non-ischaemic cardiomyopathy, survivors of out-of-hospital cardiac arrest, and patients with heritable arrhythmia syndromes (hypertrophic cardiomyopathy, long QT syndrome, Brugada syndrome, arrhythmogenic cardiomyopathy).

Catheter ablation is indicated for supraventricular tachycardias (SVTs) including atrioventricular nodal reentrant tachycardia (AVNRT — the most common SVT), atrioventricular reentrant tachycardia via accessory pathways (WPW syndrome), typical atrial flutter (cavotricuspid isthmus-dependent), focal atrial tachycardia, and atrial fibrillation. Ventricular premature contractions causing symptoms or cardiomyopathy (PVC-induced cardiomyopathy) and ventricular tachycardia (especially in structural heart disease or channelopathies) are ablated at specialist electrophysiology centres.

Pacemaker implantation is indicated for patients with symptomatic bradyarrhythmias (syncope, near-syncope, heart failure, or exercise intolerance attributable to bradycardia) or high-risk asymptomatic AV block. ICD implantation is recommended by ACC/AHA and ESC guidelines for primary prevention in patients with ischaemic cardiomyopathy and LVEF below 35% despite optimal medical therapy for at least 3 months (with the MADIT II and SCD-HeFT trials establishing this indication), and for secondary prevention in all survivors of haemodynamically significant ventricular arrhythmias or cardiac arrest without a fully reversible cause.

Catheter ablation is appropriate for patients with symptomatic SVT where drug therapy is ineffective, not tolerated, or not preferred; for high-risk accessory pathways (short refractory period with risk of rapid conduction during AF causing ventricular fibrillation); for typical atrial flutter (where ablation is first-line rather than antiarrhythmic drugs); and for atrial fibrillation after failure of at least one antiarrhythmic agent or as first-line in patients who prefer ablation over lifelong antiarrhythmic medication. Pacemaker implantation is not indicated for asymptomatic bradycardia without evidence of haemodynamic compromise, and ICD implantation is not indicated where life expectancy is limited by non-cardiac disease.

Modern pacemakers are available in single-chamber (right ventricle only, for AF with AV block), dual-chamber (atrium and right ventricle, maintaining AV synchrony — preferred for sinus node disease), and physiological pacing systems. Leadless pacemakers (Micra, EV-ICD) are implanted directly in the right ventricle via a transcatheter approach, avoiding the risk of lead complications and pocket infections at the cost of a single-chamber pacing only option. Conduction system pacing — His bundle pacing or left bundle branch area (LBBA) pacing — delivers more physiological pacing by engaging the native conduction system rather than pacing the right ventricular apex, reducing the risk of pacemaker-induced cardiomyopathy in patients with normal AV conduction who require frequent pacing.

Subcutaneous ICDs (S-ICD) avoid endovascular leads entirely, instead sensing and shocking through subcutaneous electrodes, eliminating transvenous lead complications but unable to provide pacing therapy. Wearable cardioverter-defibrillators (WCDs) provide temporary ICD protection during periods of uncertain LVEF recovery (e.g., post-myocardial infarction) without requiring implantation. Catheter ablation uses either radiofrequency (heat-based) or cryothermy (freeze-based, preferred near the AV node) energy. Contact force sensing catheters measure the physical pressure of electrode-tissue contact, enabling ablation lesion quality optimisation and reducing the risk of perforation. Remote magnetic navigation (Niobe system) allows catheter manipulation from outside the radiation environment, reducing operator radiation exposure. Tissue contact, enabling ablation lesion quality optimisation and reducing the risk of perforation. Cryoablation is preferred over RF for paediatric EP procedures and selected arrhythmias near the AV node due to its more predictable and reversible tissue effect.

Permanent pacing completely eliminates symptoms of bradycardia — syncope, dizziness, and breathlessness — in over 95% of patients with appropriate device programming. ICD therapy reduces sudden cardiac death risk in primary prevention patients with LVEF below 35% by approximately 30% relative risk reduction (NNT approximately 12–18 patients treated per sudden death prevented over 5 years, from the MADIT II and SCD-HeFT trials). Secondary prevention ICD implantation reduces recurrent sudden cardiac arrest mortality by 20–25% versus antiarrhythmic drug therapy at 3 years.

Catheter ablation of AVNRT achieves a cure rate exceeding 97% with recurrence rates below 5% and a risk of AV block requiring pacemaker implantation below 0.5%. WPW ablation achieves a cure rate of 95% for accessory pathway ablation. Typical atrial flutter ablation achieves 95% freedom from flutter. Single-procedure AF ablation achieves freedom from AF in 70–80% of paroxysmal AF patients and 50–65% of persistent AF patients at 12 months, with multiple procedures achieving over 80% success at 3 years.

Pacemaker and ICD implantation risks include pocket haematoma (3–5%), lead displacement (1–3%, most common in the first month), pneumothorax from subclavian vein access (1%), infection of the device pocket (1–2%, with serious infection rates of 0.5–1% requiring complete system extraction), and cardiac perforation from lead placement (rare, 0.1–0.2%). Long-term lead fracture or insulation breach occurs in 1–2% of leads per year and may cause inappropriate shocks (ICD) or loss of pacing.

Catheter ablation complications depend on the arrhythmia and approach: transseptal puncture for left-sided ablation carries 0.5–1% risk of pericardial tamponade; AF ablation carries 0.02–0.04% risk of the life-threatening atrioesophageal fistula complication; stroke risk during AF ablation is 0.5–1%; pulmonary vein stenosis 1–3%. Inappropriate ICD shocks — shocks delivered for non-life-threatening arrhythmias or device malfunction — affect 15–20% of ICD patients per year and cause significant psychological distress; modern ICD programming algorithms have substantially reduced this rate.

Pacemaker and ICD implantation require 1–2 days of hospitalisation for device testing, wound care, and observation. The arm on the side of implantation must not be raised above shoulder height for 4–6 weeks while the leads fix into position. Device clinic follow-up at 6 weeks, 6 months, and annually thereafter (or via remote monitoring for modern devices) checks lead parameters (impedance, sensing, pacing thresholds), battery longevity, and stored arrhythmia episodes. Device battery life is 7–12 years for pacemakers and 5–9 years for ICDs, after which a generator change procedure is required.

Catheter ablation patients are observed overnight and discharged the following day. Anticoagulation post-AF ablation continues for at least 2 months (and indefinitely in patients with high stroke risk) to cover the healing endocardial surface. A 3-month blanking period during which early recurrences may settle spontaneously is standard. Ambulatory cardiac monitoring (long-term Holter, implantable loop recorder) at 3, 6, and 12 months assesses success. Return to normal activity occurs within 2–5 days of ablation.

Pacemaker implantation in the United States costs $15,000–$50,000 depending on device complexity; ICD implantation $35,000–$80,000; and CRT-D (cardiac resynchronisation therapy-defibrillator) $60,000–$100,000. Catheter ablation for AF in the US costs $25,000–$50,000 per procedure. In the UK, these procedures are provided free on the NHS, though waiting times can be substantial. Private costs in the UK range from £8,000 to £25,000 for device implantation.

In India, permanent pacemaker implantation (including device and procedure) costs approximately $2,500–$6,000 — compared to $15,000–$50,000 in the US. ICD implantation at leading Indian centres costs $8,000–$20,000; AF ablation costs $5,000–$10,000. Indian centres including Fortis Escorts Heart Institute, Apollo Hospitals, and Medanta host internationally trained cardiac electrophysiologists with decades of experience and high procedural volumes. Thailand (Bumrungrad, Bangkok Heart Hospital), Turkey (Acibadem), and Singapore (National Heart Centre) are additional centres where EP procedures are performed to international standards with significant cost savings.

For bradyarrhythmia management, temporary pacing during reversible causes (acute myocardial infarction, drug toxicity, metabolic disturbance) can bridge the patient to recovery without permanent device implantation. Transcutaneous pacing provides immediate non-invasive pacing in emergency situations. For SVTs, vagal manoeuvres (Valsalva, carotid sinus massage), intravenous adenosine, or oral antiarrhythmic drugs (beta-blockers, flecainide, verapamil) provide acute and long-term rhythm control as alternatives to catheter ablation, though with lower long-term success rates and the burden of ongoing medication.

For patients with AF who decline or are not candidates for ablation, rate control (slowing the ventricular response to AF using beta-blockers, digoxin, or calcium channel blockers without attempting to restore sinus rhythm) combined with anticoagulation for stroke prevention is an effective long-term management strategy, as established by the AFFIRM and RACE trials. The EAST-AFNET 4 trial demonstrated that early rhythm control (with either antiarrhythmic drugs or ablation) reduces cardiovascular events compared to rate control, shifting the paradigm toward earlier rhythm control intervention.